Journal Information
Vol. 40. Issue 8.
Pages 386 (August 2004)
Share
Share
Download PDF
More article options
Vol. 40. Issue 8.
Pages 386 (August 2004)
Full text access
Respuesta de los autores
Visits
5211
I. Sampablo Lauroa, J.I. Izquierdob
a Servicio de Neumología. Hospital Sagrat Cor. Barcelona. España
b Servicio de Neumología. Hospital General.Guadalajara. España
This item has received
Article information
Full text is only aviable in PDF
Bibliografía
[1.]
D.R. Shalinsky, J. Brekken, H. Zou.
Marked antiangiogenic and antitumor efficacy of AG3340 in chemoresistant human non small cell lung cancer tumors: single agent and combination chemotherapy studies.
Clin Cancer Res, 5 (1999), pp. 1905-1917
[2.]
C. Richardson, R. Sharma, G. Cox, K. O'Byrne.
Epidermal growth factor receptor and cyclooxygenase- 2 in non-small cell lung cancer: potential targets for chemoprevention and treatment.
Lung Cancer, 39 (2003), pp. 1-13
[3.]
I. Sampablo Lauro, J.L. Izquierdo.
¿Cuál debe ser el papel del neumólogo en el tratamiento quimioterapéutico del cáncer de pulmón?.
Arch Bronconeumol, 39 (2003), pp. 483-484
[4.]
J. Dijkman, J. Martínez González del Tio, R. Loddenkemper, K. Prowse, N. Siafakas.
Report of the working party of the “UEMS Monospeciality section of Pneumology” on training requeriments and facilities in Europe.
Eur Respir J, 7 (1994), pp. 1019-1022
[5.]
L. Hyde, C. Hyde.
Clinical manifestations of lung cancer.
Chest, 65 (1974), pp. 299-306
Copyright © 2004. Sociedad Española de Neumología y Cirugía Torácica
Archivos de Bronconeumología
Article options
Tools

Are you a health professional able to prescribe or dispense drugs?